<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644629</url>
  </required_header>
  <id_info>
    <org_study_id>SHA-15-0019</org_study_id>
    <nct_id>NCT02644629</nct_id>
  </id_info>
  <brief_title>Intra-nasal vs. Intra-venous Ketamine Administration</brief_title>
  <official_title>Intra-nasal vs. Intra-venous Ketamine Administration as an add-on to Antidepressant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study wishes to contribute to the applicability of the use of ketamine in a
      clinical setting by focusing on the efficacy of intra-nasal administration compared with the
      IV route.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MADRS (Montgomery-Ã…sberg Depression Rating Scale) score improvement from baseline</measure>
    <time_frame>15 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of subjects achieving remission</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of subjects achieving Response</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of anti-depressant effect according to MADRS Score</measure>
    <time_frame>15 weeks</time_frame>
    <description>The rate of effect decline, as measured by MADRS Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Route, based on side effects questionnaire</measure>
    <time_frame>3 weeks</time_frame>
    <description>Adverse side effects reported by subjects, as reported in side effects questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Active IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive IV Ketamine, along with IN placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active IN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive IN Ketamine, along with IV placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)</description>
    <arm_group_label>Active IV</arm_group_label>
    <arm_group_label>Active IN</arm_group_label>
    <other_name>Saline 0.9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine (1st phase)</intervention_name>
    <description>Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)</description>
    <arm_group_label>Active IV</arm_group_label>
    <arm_group_label>Active IN</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine (2st phase)</intervention_name>
    <description>Patients failing to achieve response (&lt;50% MADRS score) in the parallal phase, will be offered additional 4 session (twice a week, 2 weeks) of 0.5 mg/kg ketamine over 40 minutes.</description>
    <arm_group_label>Active IV</arm_group_label>
    <arm_group_label>Active IN</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-65

          2. Diagnosis of MDD (Major Depressive Disorder), made or affirmed by a senior
             psychiatrist in Shalvata

          3. MADRS score &gt; 20

          4. Treated with conventional anti-depressant, administered within a formal psychiatric
             clinic or by a certified psychiatrist.

        Exclusion Criteria:

          1. Active or past psychotic disorder, including a history of psychotic affective state

          2. Mental Retardation or Autistic Spectrum Disorder

          3. Prominent personality disorder

          4. Cardiac or neurologic active medical condition, including past CVA/TIA (Cardiovascular
             Accident/Transient Ischemic Attack) or any other unstable medical condition.

          5. Chronic nasal congestion

          6. Active or recent drug or alcohol abuse

          7. Substantial suicidality in a patient requiring admission but refuses to do so, and
             signs an &quot;against medical advice&quot; release form as part of clinical evaluation, and
             does not answer the terms for involuntary admission.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aviv Segev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shalvata MHC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aviv Segev, MD</last_name>
    <phone>+972-9-7478-638</phone>
    <email>aviv.segev@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shalvata MHC</name>
      <address>
        <city>Hod Hasharon</city>
        <zip>POB 94</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aviv Segev, MD</last_name>
      <phone>+972-9-7478-638</phone>
      <email>aviv.segev@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shalvata Mental Health Center</investigator_affiliation>
    <investigator_full_name>Aviv Segev</investigator_full_name>
    <investigator_title>Head, Psychiatric Emergency Services</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

